Cannabix Technologies Makes First Commercial Delivery of Breath-Based Multi-Drug Test Panel

10:13 AM EDT, 10/20/2026 (MT Newswires) -- Cannabix Technologies (BLO.CN) made its first commercial delivery of its new breath-based multi-drug test panel, it said Tuesday. The panel, modeled after the drug classes included in the US Department of Transportation's (DOT) federally mandated urine drug testing program, is targeted toward "workplace testing, criminal justice and treatment monitoring programs, post-incident investigations, reasonable-suspicion testing, and other safety-sensitive environments," said the company. "Breath testing is intended to target a substantially shorter detection window following drug consumption," added the company. "Cannabix's breath-testing technology is designed to help address this gap by focusing on a shorter detection period, ranging from 15 minutes to 4 hours after use, which provides a more relevant time window in safety-sensitive situations." Shares of the company were last seen up CA$0.03 or 9.5% to CA$0.345 on the Canadian Securities Exchange. Price: 0.35, Change: +0.03, Percent Change: +9.52